Is the association between inhaled beta-agonist use and life-threatening asthma because of confounding by severity?

P. Ernst, B. Habbick, S. Suissa, B. Hemmelgarn, D. Cockcroft, A (Sonia) Buist, R. I. Horwitz, M. McNutt, W. O. Spitzer

Research output: Contribution to journalArticle

96 Citations (Scopus)

Abstract

We have previously reported an increasing dose-response relationship between the regular use of beta-agonist inhalers and the risk of asthma death and near death among a cohort of 12,301 subjects who had been dispensed 10 or more prescriptions of asthma drugs from January 1980 to April 1987. That analysis was based solely on information obtained from linkable computerized data bases. Such an association might be explained in part by the tendency of patients with more severe asthma, that is, those at greatest risk for an adverse outcome, to use more beta-agonist medication. To further examine this potential confounding by severity, we gathered clinical information independently from the field on the 129 case patients and their 655 control patients from the matched case-control analysis of 12,301 subjects. In 68% of the control patients with a life-threatening episode and 75% of the matched control subjects, we obtained a valid questionnaire from at least one physician who had seen the patient during the previous 2 yr. Acceptable information on hospitalizations because of asthma was obtained in 87% of those hospitalized. Clinical features associated with an increased risk of fatal and near-fatal asthma were: a history of loss of consciousness or seizures during a previous asthma attack (odds ratio, 10.2; 95% Cl, 3.9 to 26.7), a history of attacks of asthma precipitated by eating certain foods (odds ratio, 5.1; 95% Cl, 2.4 to 11.1), a clinical score designed to reflect the severity of prior attacks of asthma leading to hospitalization, and prior respiratory acidosis among those in whom a blood gas determination was recorded. After adjustment for these clinical markers of asthma severity, there was no significant reduction in the odds ratio for asthma death and near death per metered-dose inhaler of fenoterol (e.g., odds ratio, 2.5; 95% Cl, 1.7 to 3.8) or albuterol (e.g., odds ratio, 2.0; 95% Cl, 1.5 to 2.7). We conclude that this further attempt at adjusting for confounding by severity did not alter the relationship between the use of beta-agonist inhalers by subjects outside of hospital and the risk of asthma death and near death.

Original languageEnglish (US)
Pages (from-to)75-79
Number of pages5
JournalAmerican Review of Respiratory Disease
Volume148
Issue number1
StatePublished - 1993
Externally publishedYes

Fingerprint

Asthma
Odds Ratio
Nebulizers and Vaporizers
Hospitalization
Fenoterol
Respiratory Acidosis
Metered Dose Inhalers
Unconsciousness
Prescription Drugs
Albuterol
Seizures
Eating
Biomarkers
Gases
Databases
Physicians
Food

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Ernst, P., Habbick, B., Suissa, S., Hemmelgarn, B., Cockcroft, D., Buist, A. S., ... Spitzer, W. O. (1993). Is the association between inhaled beta-agonist use and life-threatening asthma because of confounding by severity? American Review of Respiratory Disease, 148(1), 75-79.

Is the association between inhaled beta-agonist use and life-threatening asthma because of confounding by severity? / Ernst, P.; Habbick, B.; Suissa, S.; Hemmelgarn, B.; Cockcroft, D.; Buist, A (Sonia); Horwitz, R. I.; McNutt, M.; Spitzer, W. O.

In: American Review of Respiratory Disease, Vol. 148, No. 1, 1993, p. 75-79.

Research output: Contribution to journalArticle

Ernst, P, Habbick, B, Suissa, S, Hemmelgarn, B, Cockcroft, D, Buist, AS, Horwitz, RI, McNutt, M & Spitzer, WO 1993, 'Is the association between inhaled beta-agonist use and life-threatening asthma because of confounding by severity?', American Review of Respiratory Disease, vol. 148, no. 1, pp. 75-79.
Ernst, P. ; Habbick, B. ; Suissa, S. ; Hemmelgarn, B. ; Cockcroft, D. ; Buist, A (Sonia) ; Horwitz, R. I. ; McNutt, M. ; Spitzer, W. O. / Is the association between inhaled beta-agonist use and life-threatening asthma because of confounding by severity?. In: American Review of Respiratory Disease. 1993 ; Vol. 148, No. 1. pp. 75-79.
@article{3d0ce44c08c64e939e8042d800eba4dc,
title = "Is the association between inhaled beta-agonist use and life-threatening asthma because of confounding by severity?",
abstract = "We have previously reported an increasing dose-response relationship between the regular use of beta-agonist inhalers and the risk of asthma death and near death among a cohort of 12,301 subjects who had been dispensed 10 or more prescriptions of asthma drugs from January 1980 to April 1987. That analysis was based solely on information obtained from linkable computerized data bases. Such an association might be explained in part by the tendency of patients with more severe asthma, that is, those at greatest risk for an adverse outcome, to use more beta-agonist medication. To further examine this potential confounding by severity, we gathered clinical information independently from the field on the 129 case patients and their 655 control patients from the matched case-control analysis of 12,301 subjects. In 68{\%} of the control patients with a life-threatening episode and 75{\%} of the matched control subjects, we obtained a valid questionnaire from at least one physician who had seen the patient during the previous 2 yr. Acceptable information on hospitalizations because of asthma was obtained in 87{\%} of those hospitalized. Clinical features associated with an increased risk of fatal and near-fatal asthma were: a history of loss of consciousness or seizures during a previous asthma attack (odds ratio, 10.2; 95{\%} Cl, 3.9 to 26.7), a history of attacks of asthma precipitated by eating certain foods (odds ratio, 5.1; 95{\%} Cl, 2.4 to 11.1), a clinical score designed to reflect the severity of prior attacks of asthma leading to hospitalization, and prior respiratory acidosis among those in whom a blood gas determination was recorded. After adjustment for these clinical markers of asthma severity, there was no significant reduction in the odds ratio for asthma death and near death per metered-dose inhaler of fenoterol (e.g., odds ratio, 2.5; 95{\%} Cl, 1.7 to 3.8) or albuterol (e.g., odds ratio, 2.0; 95{\%} Cl, 1.5 to 2.7). We conclude that this further attempt at adjusting for confounding by severity did not alter the relationship between the use of beta-agonist inhalers by subjects outside of hospital and the risk of asthma death and near death.",
author = "P. Ernst and B. Habbick and S. Suissa and B. Hemmelgarn and D. Cockcroft and Buist, {A (Sonia)} and Horwitz, {R. I.} and M. McNutt and Spitzer, {W. O.}",
year = "1993",
language = "English (US)",
volume = "148",
pages = "75--79",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "1",

}

TY - JOUR

T1 - Is the association between inhaled beta-agonist use and life-threatening asthma because of confounding by severity?

AU - Ernst, P.

AU - Habbick, B.

AU - Suissa, S.

AU - Hemmelgarn, B.

AU - Cockcroft, D.

AU - Buist, A (Sonia)

AU - Horwitz, R. I.

AU - McNutt, M.

AU - Spitzer, W. O.

PY - 1993

Y1 - 1993

N2 - We have previously reported an increasing dose-response relationship between the regular use of beta-agonist inhalers and the risk of asthma death and near death among a cohort of 12,301 subjects who had been dispensed 10 or more prescriptions of asthma drugs from January 1980 to April 1987. That analysis was based solely on information obtained from linkable computerized data bases. Such an association might be explained in part by the tendency of patients with more severe asthma, that is, those at greatest risk for an adverse outcome, to use more beta-agonist medication. To further examine this potential confounding by severity, we gathered clinical information independently from the field on the 129 case patients and their 655 control patients from the matched case-control analysis of 12,301 subjects. In 68% of the control patients with a life-threatening episode and 75% of the matched control subjects, we obtained a valid questionnaire from at least one physician who had seen the patient during the previous 2 yr. Acceptable information on hospitalizations because of asthma was obtained in 87% of those hospitalized. Clinical features associated with an increased risk of fatal and near-fatal asthma were: a history of loss of consciousness or seizures during a previous asthma attack (odds ratio, 10.2; 95% Cl, 3.9 to 26.7), a history of attacks of asthma precipitated by eating certain foods (odds ratio, 5.1; 95% Cl, 2.4 to 11.1), a clinical score designed to reflect the severity of prior attacks of asthma leading to hospitalization, and prior respiratory acidosis among those in whom a blood gas determination was recorded. After adjustment for these clinical markers of asthma severity, there was no significant reduction in the odds ratio for asthma death and near death per metered-dose inhaler of fenoterol (e.g., odds ratio, 2.5; 95% Cl, 1.7 to 3.8) or albuterol (e.g., odds ratio, 2.0; 95% Cl, 1.5 to 2.7). We conclude that this further attempt at adjusting for confounding by severity did not alter the relationship between the use of beta-agonist inhalers by subjects outside of hospital and the risk of asthma death and near death.

AB - We have previously reported an increasing dose-response relationship between the regular use of beta-agonist inhalers and the risk of asthma death and near death among a cohort of 12,301 subjects who had been dispensed 10 or more prescriptions of asthma drugs from January 1980 to April 1987. That analysis was based solely on information obtained from linkable computerized data bases. Such an association might be explained in part by the tendency of patients with more severe asthma, that is, those at greatest risk for an adverse outcome, to use more beta-agonist medication. To further examine this potential confounding by severity, we gathered clinical information independently from the field on the 129 case patients and their 655 control patients from the matched case-control analysis of 12,301 subjects. In 68% of the control patients with a life-threatening episode and 75% of the matched control subjects, we obtained a valid questionnaire from at least one physician who had seen the patient during the previous 2 yr. Acceptable information on hospitalizations because of asthma was obtained in 87% of those hospitalized. Clinical features associated with an increased risk of fatal and near-fatal asthma were: a history of loss of consciousness or seizures during a previous asthma attack (odds ratio, 10.2; 95% Cl, 3.9 to 26.7), a history of attacks of asthma precipitated by eating certain foods (odds ratio, 5.1; 95% Cl, 2.4 to 11.1), a clinical score designed to reflect the severity of prior attacks of asthma leading to hospitalization, and prior respiratory acidosis among those in whom a blood gas determination was recorded. After adjustment for these clinical markers of asthma severity, there was no significant reduction in the odds ratio for asthma death and near death per metered-dose inhaler of fenoterol (e.g., odds ratio, 2.5; 95% Cl, 1.7 to 3.8) or albuterol (e.g., odds ratio, 2.0; 95% Cl, 1.5 to 2.7). We conclude that this further attempt at adjusting for confounding by severity did not alter the relationship between the use of beta-agonist inhalers by subjects outside of hospital and the risk of asthma death and near death.

UR - http://www.scopus.com/inward/record.url?scp=0027298483&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027298483&partnerID=8YFLogxK

M3 - Article

C2 - 8100409

AN - SCOPUS:0027298483

VL - 148

SP - 75

EP - 79

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 1

ER -